Shares of Global Blood Therapeutics Inc. were up 34.4% in premarket trading on Thursday after Bloomberg reported that the company is “attracting takeover interest,” citing people familiar with the matter. Global Blood Therapeutics markets a treatment for sickle-cell disease called Oxbryta, which generated $194.7 million in revenue in 2021. The company’s stock is up 15.9% this year, while the S&P 500 is down 12.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.